ONCY PE Ratio & Valuation,Is ONCY Overvalued

ONCY Relative Valuation

ONCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ONCY is overvalued; if below, it's undervalued.

Historical Valuation

Oncolytics Biotech Inc (ONCY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.71. The fair price of Oncolytics Biotech Inc (ONCY) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：0.92

Fair

-4.64

-2.57

EV/EBITDA

Oncolytics Biotech Inc. (ONCY) has a current EV/EBITDA of -2.57. The 5-year average EV/EBITDA is -2.71. The thresholds are as follows: Strongly Undervalued below -5.73, Undervalued between -5.73 and -4.22, Fairly Valued between -1.20 and -4.22, Overvalued between -1.20 and 0.32, and Strongly Overvalued above 0.32. The current Forward EV/EBITDA of -2.57 falls within the Historic Trend Line -Fairly Valued range.

-2.98

EV/EBIT

Oncolytics Biotech Inc. (ONCY) has a current EV/EBIT of -2.98. The 5-year average EV/EBIT is -2.88. The thresholds are as follows: Strongly Undervalued below -6.03, Undervalued between -6.03 and -4.46, Fairly Valued between -1.31 and -4.46, Overvalued between -1.31 and 0.26, and Strongly Overvalued above 0.26. The current Forward EV/EBIT of -2.98 falls within the Historic Trend Line -Fairly Valued range.

0.00

Oncolytics Biotech Inc. (ONCY) has a current PS of 0.00. The 5-year average PS is 21.67. The thresholds are as follows: Strongly Undervalued below -60.24, Undervalued between -60.24 and -19.28, Fairly Valued between 62.63 and -19.28, Overvalued between 62.63 and 103.58, and Strongly Overvalued above 103.58. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.28

P/OCF

Oncolytics Biotech Inc. (ONCY) has a current P/OCF of -2.28. The 5-year average P/OCF is -3.88. The thresholds are as follows: Strongly Undervalued below -7.84, Undervalued between -7.84 and -5.86, Fairly Valued between -1.90 and -5.86, Overvalued between -1.90 and 0.09, and Strongly Overvalued above 0.09. The current Forward P/OCF of -2.28 falls within the Historic Trend Line -Fairly Valued range.

-1.68

P/FCF

Oncolytics Biotech Inc. (ONCY) has a current P/FCF of -1.68. The 5-year average P/FCF is -3.07. The thresholds are as follows: Strongly Undervalued below -6.19, Undervalued between -6.19 and -4.63, Fairly Valued between -1.51 and -4.63, Overvalued between -1.51 and 0.05, and Strongly Overvalued above 0.05. The current Forward P/FCF of -1.68 falls within the Historic Trend Line -Fairly Valued range.

Oncolytics Biotech Inc (ONCY) has a current Price-to-Book (P/B) ratio of 1150.19. Compared to its 3-year average P/B ratio of 111.01 , the current P/B ratio is approximately 936.15% higher. Relative to its 5-year average P/B ratio of 67.92, the current P/B ratio is about 1593.52% higher. Oncolytics Biotech Inc (ONCY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -22.88%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -21.23% , the current FCF yield is about -100.00% lower.

1289.98

P/B

Median3y

111.01

Median5y

67.92

-19.63

FCF Yield

Median3y

-22.88

Median5y

-21.23

Competitors Valuation Multiple

The average P/S ratio for ONCY's competitors is 0.00, providing a benchmark for relative valuation. Oncolytics Biotech Inc Corp (ONCY) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ONCY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ONCY in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Oncolytics Biotech Inc (ONCY) currently overvalued or undervalued?

What is Oncolytics Biotech Inc (ONCY) fair value?

ONCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Oncolytics Biotech Inc (ONCY) is between to according to relative valuation methord.

How does ONCY's valuation metrics compare to the industry average?

What is the current P/B ratio for Oncolytics Biotech Inc (ONCY) as of Dec 17 2025?

As of Dec 17 2025, Oncolytics Biotech Inc (ONCY) has a P/B ratio of 1150.19. This indicates that the market values ONCY at 1150.19 times its book value.

What is the current FCF Yield for Oncolytics Biotech Inc (ONCY) as of Dec 17 2025?

As of Dec 17 2025, Oncolytics Biotech Inc (ONCY) has a FCF Yield of 0.00%. This means that for every dollar of Oncolytics Biotech Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Oncolytics Biotech Inc (ONCY) as of Dec 17 2025?

As of Dec 17 2025, Oncolytics Biotech Inc (ONCY) has a Forward P/E ratio of -4.13. This means the market is willing to pay $-4.13 for every dollar of Oncolytics Biotech Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Oncolytics Biotech Inc (ONCY) as of Dec 17 2025?

As of Dec 17 2025, Oncolytics Biotech Inc (ONCY) has a Forward P/S ratio of 0.00. This means the market is valuing ONCY at $0.00 for every dollar of expected revenue over the next 12 months.

ONCY Valuation